Comparative Pharmacokinetics of a Compounded 6-mercaptopurine Liquid Formulation Preparation and Tablets

Comparative Pharmacokinetics of a Compounded 6-mercaptopurine Liquid Formulation Preparation and Tablets

The purpose of this study is to compare the pharmacokinetics of a routinely used compounded liquid formulation of 6-mercaptopurine (6-MP) with commercially available tablets in patients who are receiving treatment with 6-MP as part of their clinical treatment for acute lymphoblastic leukemia (ALL).

Inclusion Criteria:

• Patients ages 4-17 years of age who are receiving maintenance chemotherapy treatment for ALL with 6-MP will be included.

Exclusion Criteria:

• Inability to have blood drawn for the screening lab tests
• Received methotrexate or folate supplement within the last 24 hours
• Pregnant or lactating females
• Inability to swallow a pill
• Hemoglobin less or equal to 8 gm/dl
• Presence of significant co-morbid illness that makes child ineligible as deemed by the investigator
• Weight < or = 16 kg